Offer Request Form

Order list is empty

Shikari® (Q-VEDO) Vedolizumab ELISA

Enzyme immunoassay for the quantitative determination of Vedolizumab (Entyvio®) in serum and plasma.

This kit has been especially developed for the quantitative determination of vedolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Vedolizumab Drug Bank Accession Number is DB09033.

Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohn's disease for patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies.

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact


Required Volume (µl) 10
Total Time (min) 100
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 1,56
Spike Recovery (%) Between 85-115
Shelf Life (year) 1
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download
Validation Report Download

Publications with this drug

# File Action